Mark A. Rubin
Impact in
- Cancer Research top 0.02%
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
- Pulmonary and Respiratory Medicine top 0.01%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Papers in
-
- Prostate Cancer Treatment and Research 197
- Prostate Cancer Diagnosis and Treatment 108
-
- Molecular Biology Techniques and Applications 37
- Cancer-related gene regulation 31
- Ubiquitin and proteasome pathways 28
- Co-authors
- Arul M. Chinnaiyan (60 shared papers)Kenneth J. Pienta (32 shared papers)Sooryanarayana Varambally (26 shared papers)Rajal B. Shah (30 shared papers)Scott A. Tomlins (41 shared papers)Debashis Ghosh (12 shared papers)Saravana M. Dhanasekaran (15 shared papers)Francesca Demichelis (68 shared papers)
- Journals
- The Journal of Urology (42 papers)Cancer Research (38 papers)Journal of Clinical Oncology (26 papers)Urology (20 papers)Neoplasia (20 papers)
- Partner nations
- United StatesSwitzerlandGermany
In The Last Decade
Mark A. Rubin
541 papers receiving 49.3k citations
Mark A. Rubin's Hit Papers
Peers
Comparison fields: 5 of 205
- Cancer Research 10.9k
- Pulmonary and Respiratory Medicine 20.1k
- Molecular Biology 23.2k
- Oncology 8.5k
- Immunology and Allergy 905
Countries citing papers authored by Mark A. Rubin
This map shows the geographic impact of Mark A. Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Rubin more than expected).
Fields of papers citing papers by Mark A. Rubin
This network shows the impact of papers produced by Mark A. Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Rubin. The network helps show where Mark A. Rubin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark A. Rubin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 552 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer Hit paper breakdown → | 2005 | 2847 |
| 2 | The polycomb group protein EZH2 is involved in progression of prostate cancer Hit paper breakdown → | 2002 | 2110 |
| 3 | Delineation of prognostic biomarkers in prostate cancer Hit paper breakdown → | 2001 | 1330 |
| 4 | EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Hit paper breakdown → | 2003 | 1310 |
| 5 | Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma Hit paper breakdown → | 2005 | 1114 |
| 6 | Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer Hit paper breakdown → | 2016 | 1092 |
| 7 | Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer Hit paper breakdown → | 2006 | 845 |
| 8 | Integrative molecular concept modeling of prostate cancer progression Hit paper breakdown → | 2006 | 697 |
| 9 | Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression Hit paper breakdown → | 2005 | 616 |
| 10 | Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer Hit paper breakdown → | 2007 | 614 |
| 11 | Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Hit paper breakdown → | 2002 | 517 |
| 12 | Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer Hit paper breakdown → | 2008 | 516 |
| 13 | I NTERGROUP B IAS Hit paper breakdown → | 2002 | 504 |
| 14 | Suppression of insulin feedback enhances the efficacy of PI3K inhibitors Hit paper breakdown → | 2018 | 503 |
| 15 | 2002 | 493 | |
| 16 | 2007 | 489 | |
| 17 | 2004 | 485 | |
| 18 | 2004 | 479 | |
| 19 | 2005 | 467 | |
| 20 | The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours Hit paper breakdown → | 2022 | 441 |
About Mark A. Rubin
Mark A. Rubin is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, Oncology and Surgery, having authored 552 papers that have together received 50.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (197 papers), Prostate Cancer Diagnosis and Treatment (108 papers), Cancer Genomics and Diagnostics (50 papers), Molecular Biology Techniques and Applications (37 papers), Cancer, Lipids, and Metabolism (33 papers), Cancer-related gene regulation (31 papers), Ubiquitin and proteasome pathways (28 papers) and Radiopharmaceutical Chemistry and Applications (22 papers). The work is most often cited by research in Cancer Research (10.9k citations), Pulmonary and Respiratory Medicine (20.1k citations), Molecular Biology (23.2k citations), Oncology (8.5k citations) and Immunology and Allergy (905 citations). Mark A. Rubin has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Arul M. Chinnaiyan, Kenneth J. Pienta, Sooryanarayana Varambally, Rajal B. Shah, Scott A. Tomlins, Debashis Ghosh, Saravana M. Dhanasekaran, Francesca Demichelis, Sven Perner and Rohit Mehra. Their work appears in journals such as The Journal of Urology, Cancer Research, Journal of Clinical Oncology, Urology and Neoplasia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.